Retail level recall of eight brands of ranitidine products found to contain NDMA

The Health Sciences Authority (HSA) would like to inform healthcare professionals on the retail level recall of eight brands of ranitidine products detected to contain a nitrosamine impurity, N-nitrosodimethylamine (NDMA), that exceeded internationally acceptable level. All locally marketed ranitidine products (with the exception of Gastril Injection) are being recalled. Healthcare professionals are advised to stop prescribing or dispensing the affected ranitidine products and return the remaining stocks to the respective companies. As the potential risks are associated with long term exposure, patients prescribed the affected ranitidine products may continue with their medicines. Please refer to the letter for further details.
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.